John Libbey Eurotext

European Journal of Dermatology


Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden – a cross-sectional study Volume 22, issue 2, March-April 2012


See all figures

The Swedish Institute for Health Economics, Box 2127, 220 02 Lund, Sweden, Abbott Scandinavia AB, Solna, Sweden, Department of Dermatology, Kristianstad Hospital, Sweden, Department of Dermatology, University of Lund, Malmö, Sweden
  • Key words: psoriasis, cost of illness, quality of life, biologic systemic treatment, Sweden
  • DOI : 10.1684/ejd.2011.1635
  • Page(s) : 238-45
  • Published in: 2012

Objectives: Knowledge of the societal costs of psoriasis is limited. This study estimated the cost of care, psoriasis area and severity index (PASI), and quality of life in a defined patient population in Sweden. Methods: A prevalence-based prospective recruitment of patients visiting two Swedish dermatology clinics between September and December 2009 was performed, collecting resource utilization for health care contacts, treatment, travelling, and productivity loss during 1 month. Results: 164 patients were included. Mean total cost per patient-month was 994€. Main cost drivers were outpatient visits and light therapy (49%), biological drugs (20%) and productivity loss (22%). Total cost for topical treatment only (TT; 34%) was 369€, light therapy (LT; 24%) 1,274€, traditional systemic treatment (TST; 26%) 1,085€ and biological systemic treatment (BST; 16%) 1,709€ per patient-month. Main cost drivers were: outpatient visits (56%) in TT as well as for LT (78%), productivity loss (40%) in TST, and biological drugs (71%) among BST patients. There was no clear relationship between clinical (PASI) or subjective (DLQI) severity estimations and costs. Conclusions: The one-month cost-of-illness amounted to almost 1,000€/month, with great variations. Despite 1,190€ difference in drug cost for TST vs BST, total cost per month differed by 623€ because of offsets from improved productivity. A trend towards lower severity and reductions in outpatient and topical treatment costs was seen.